Schrodinger UBS Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good morning, everybody. Welcome to day two of the UBS Global Healthcare Conference. I'm Kevin Caliendo, UBS Healthcare IT and Distribution Analyst, and we are very proud and happy to have with us today management team from Schrödinger, Richie Jain, who is the Chief Financial Officer, and Pat Lorton, who is the Chief Technology Officer for software. Guys, thanks so much for having us.
Yeah, thank you for inviting us.
I should mention, I think you are the best performing stock over the last three months of the Russell 3000, or you're one of the two, up over 100%. So congratulations. I wish one of the three of us up here was smart enough to assume coverage with a buy rating three months ago when I did that. So thank you for succeeding and making me look bad. No, congratulations in all these ends. It's been fantastic to watch. Maybe before we get into the Q&A, why don't you talk a little bit and introduce everybody to Schrödinger more so?
Great. Yeah, I'm happy to do that. Thank you. Thanks. We are a computational platform for molecular discovery of high applicability to life science and material science customers.
If you look at our business, it is weighted towards life sciences, but material science is a growing part of the business. We monetize the platform through licensing of the software. That is the majority of the business. We also monetize the platform by doing our own therapeutics, and by doing collaborations and NewCos with companies in life science. If you think about our outlook and trajectory, we are a high science, high innovation company bringing new products to our customers. We are continuously evolving the platform and expanding the domain applicability beyond just small molecule discovery, but even moving into new products such as formulations, expanding in from small molecule into biologics. We have also been innovating on the AI side.
We have rolled out an agent called Bunsen, which Pat can talk about it in more detail, but it is allowing our customers and users to just gain efficiencies in running the software. We have also been evolving the business model a bit. We are focusing on the platform-centric elements of the company, so licensing software, doing early stage therapeutics. We have also announced this year that we are moving towards more hosted contracts, and focusing on ACV as a result of that.
That is helpful. You mentioned AI. We should probably start there because it seems where everybody wants to start these days. It is clearly critical. We had a CRO panel yesterday where we talked about it. You cannot talk about drug discovery and drug development without talking about AI. It is clearly critical to the future innovation for drug discovery. Can you talk a little bit about your overarching AI strategy, how you approach it, how you use it, how you promote it, even within maybe? Why don't we start there?
Yeah, sure. I would love to talk about that. What is interesting is Schrödinger had a bit of a reputation for a couple years of being, we will say, anti-AI. It was not necessarily because we are anti-AI at all. I can actually say we tried to build the Bunsen agent, the first version of that, I think a little over four years ago now, I think when ChatGPT 3.5 came out. We have wanted this level of AI, but a lot of the hype around AI was being completely oversold, and we viewed it kind of as our job to stand up for the physics-first deep calculation approach. But that was using AI to make predictions, making AI to drive the actual discovery process and run the calculation engines, similar to how AI is able to code now, similar to Claude Code, how it is dominating all coding.
We viewed that very early on as something that could be transformational, and we were lucky because the second that that actually became true, that the harnesses became good enough, that AI was actually good enough to drive drug discovery, we started building Bunsen, like the current product, I should say, instead of experimental. We had early working versions of Bunsen more than a year ago now. I think we first started talking about Bunsen Q1 last year.
Q1 of this year. Oh, I'm sorry.
Q1 of this year, yeah. By Q4 of last year, we already had our internal scientists proving that this thing works, and we're extremely bullish on its ability to really drive discovery. We've mentioned several times that a big limiting factor we've always had is there aren't enough computational chemists, talented computational chemists in the world. We'll visit users, and we have introduced three new products, and they say, "I don't have enough time to use the products I'm currently buying from you." We think not only does this solve their ability to expand the scope of prediction and drug discovery, but it also solves their ability to run it at a much greater scale. That's why we're so bullish and excited about AI.
You're solving for the chemists?
Is that in essence? We are solving for all drug discovery, actually.
I mean, you look at how powerful these engines are, and you can start thinking about biologists asking questions that only chemists could ask before. We are now at the place where we are comfortable with a biologist asking a question that not even a chemist could answer. A PhD computational chemist was required before. We are not putting computational chemists out of business. There is still a lot of stuff they have to do. But the ability to simplify some of the more straightforward tasks is really going to transform the predictive abilities in this industry.
I will just add on the AI framework, obviously, it is all about the data and it is about the model. Generating data in our field is extremely cumbersome and burdensome. There is not enough experimental data you can generate to run an AI model. You have to supplement it with simulation data, and that is what our platform does. We generate simulation data, in addition to experimental data, at a scale and throughput that you cannot replicate with experiment, and at the same accuracy as the experiment. That is how customers use our platform. It is generating simulation data to run the AI model.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
